TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23889837
Drug: Regular Treatment
Normalized name: Midol Regular
DrugBank: Sodium fluorophosphate (DB09484)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular Treatment (RT): 100 hours of speech and language therapy (2 hours per week for 50 weeks)
Study: 21510321
Drug: Lafutidine with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lafutidine with peppermint oil (10 mg lafutidine + 0.64 mL peppermint oil)
Study: 21510321
Drug: Lafutidine alone
Normalized name: lafutidine
DrugBank: Lafutidine (DB12770)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lafutidine alone (10 mg)
Study: 3415805
Drug: Ketanserin 40
Normalized name: ketanserin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin 40 mg bid for 6 weeks
Study: 28259776
Drug: Rilpivirine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilpivirine (25 mg), Emtricitabine (200 mg), Tenofovir alafenamide (25 mg)
Study: 28259776
Drug: Efavirenz (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efavirenz (600 mg), Emtricitabine (200 mg), Tenofovir disoproxil fumarate (300 mg)
Study: 17416006
Drug: 250 ml/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 ml/d amino acids PN therapy
Study: 17416006
Drug: 500 ml/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 ml/d amino acids PN therapy
Study: 17416006
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no amino acids PN therapy)
Study: 14687310
Drug: Micronutrient supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient supplement providing the reference nutrient intake for all vitamins and trace elements
Study: 7956393
Drug: OKY-046 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: OKY-046 (200 mg twice a day for 3 days, 200 mg on the fourth day)
Study: 3372915
Drug: Systemic steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic steroids pretreatment
Study: 3372915
Drug: Topical steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical steroids pretreatment
Study: 31262641
Drug: Nebulized heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized heparin (10,000 IU/4 h)
Study: 28338362
Drug: T (50
Normalized name: MICRhoGAM 250 UNT (50 MCG) Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: T (50 mg/kg BM)
Study: 28338362
Drug: C (5
Normalized name: ferric (59Fe) citrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: C (5 mg/kg BM)
Study: 28338362
Drug: C +
Normalized name: Probiotic + Colostrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: C + T (5 mg/kg BM + 50 mg/kg BM)
Study: 28338362
Drug: P (5
Normalized name: salicylic acid 2 % Topical Gel (15 ML) / salicylic acid 1 % Medicated Liquid Soap (50 ML) Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: P (5 mg/kg BM)
Study: 21418096
Drug: 6-month Diabetes
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-month Diabetes Medication Assistance Service
Study: 21418096
Drug: 12-month Diabetes
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-month Diabetes Medication Assistance Service
Study: 21418096
Drug: Diabetes Medication
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetes Medication Assistance Service (both 6 and 12 months)
Study: 18204348
Drug: Methylphenidate 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate 0.3 to 0.4 mg/kg
Study: 31253252
Drug: Spinal Manipulation
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal Manipulation Therapy (SMT)
Study: 10218691
Drug: Bupivacaine 0.5%
Normalized name: BUPivacaine 0.5% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.5% diluted 1:1 with glutathione bicarbonate Ringer solution
Study: 1982059
Drug: Propranolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (80 mg/day)
Study: 26676309
Drug: Sublingual desmopressin
Normalized name: desmopressin Sublingual Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual desmopressin (Minirin Melt) 60 μg
Study: 26676309
Drug: Sublingual desmopressin
Normalized name: desmopressin Sublingual Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual desmopressin (Minirin Melt) 120 μg
Study: 26676309
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 30 mg im ketorolac and 60 μg sublingual desmopressin
Study: 26676309
Drug: Ketorolac tromethamine
Normalized name: Ketorolac Tromethamine
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketorolac tromethamine (30 mg im)
Study: 9023388
Drug: Bepanthen cream
Normalized name: Bepanthen
DrugBank: Dexpanthenol (DB09357)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bepanthen cream applied to randomly selected parts of treatment fields
Study: 9023388
Drug: No topical
Normalized name: Altreno Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No topical ointment (control)
Study: 2003042
Drug: Inhaled beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled beclomethasone dipropionate (300 micrograms/day)
Study: 6370439
Drug: Oxaprozin 1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaprozin 1,200 mg once daily
Study: 6370439
Drug: Phenylbutazone 100
Normalized name: phenylbutazone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylbutazone 100 mg four times daily
Study: 12056707
Drug: Oral capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral capecitabine (1250 mg/m2 twice daily, on days 1‐14 every 21 days)
Study: 12056707
Drug: Intravenous 5‐FU/leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 5‐FU/leucovorin (Mayo Clinic regimen)
Study: 24801171
Drug: Oral capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral capecitabine
Study: 12056707
Drug: Intravenous 5‐FU/leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 5‐FU/leucovorin
Study: 10496113
Drug: CES plus
Normalized name: Ascorbic Acid/Calcium/Selenium/Vitamin A/Vitamin E/Zinc 250 MG-25 MG-50 MCG-5000 IU-200 IU-7.5 MG Oral Capsule, Liquid Filled [ACES PLUS ZINC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CES plus low dose caffeine (150 mg/l)
Study: 10496113
Drug: CES plus
Normalized name: Ascorbic Acid/Calcium/Selenium/Vitamin A/Vitamin E/Zinc 250 MG-25 MG-50 MCG-5000 IU-200 IU-7.5 MG Oral Capsule, Liquid Filled [ACES PLUS ZINC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CES plus medium dose caffeine (225 mg/l)
Study: 10496113
Drug: CES placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: CES placebo (68.8 g/l)
Study: 6162280
Drug: Irradiation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irradiation therapy combined with vitamin A palmitate (1.5 million IU/day; total dose 30 million IU), applied orally
Study: 7084867
Drug: Irradiation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irradiation therapy combined with vitamin A palmitate
Study: 30692558
Drug: Artemether-Lumefantrine (A-L)
Normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether-Lumefantrine (A-L) in fed state
Study: 28122892
Drug: alemtuzumab 30
Normalized name: alemtuzumab 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: alemtuzumab 30 mg by intravenous infusion every other day three times a week for 12 weeks
Study: 26100413
Drug: Once monthly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Once monthly administration of vitamin D3 (25,000 IU)
Study: 26100413
Drug: Daily administration
Normalized name: Prevpac 30mg-500mg-500mg Daily Administration Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily administration of a fixed-dose combination of vitamin D3 (800 IU) and calcium (1000 mg)
Study: 19386747
Drug: Lower protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower protein formula (1.77 and 2.2 g protein/100 kcal)
Study: 19386747
Drug: Higher protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher protein formula (2.9 and 4.4 g protein/100 kcal)
Study: 15660234
Drug: Continuous SCT
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous SCT nasal spray at a dose of 200 IU/day, plus continuously 500 mg/day elementary calcium and 0.25 microg/day 1‐alpha hydroxyvitamin D3, for 1 year
Study: 15660234
Drug: Cyclic SCT
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic SCT nasal spray at a dose of 200 IU/day on alternating 15 days per month, plus continuously 500 mg/day elementary calcium and 0.25 microg/day 1‐alpha hydroxyvitamin D3, for 1 year
Study: 15660234
Drug: Cyclic SCT
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic SCT nasal spray on 10 days consecutively per month, plus continuously 500 mg/day elementary calcium and 0.25 microg/day 1‐alpha hydroxyvitamin D3, for 1 year
Study: 12814035
Drug: G115 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: G115 100 mg bid for three months
Study: 8824658
Drug: Morning dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning dosage of 40 mg omeprazole
Study: 8824658
Drug: Evening dosage
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Evening dosage of 40 mg omeprazole
Study: 26927479
Drug: APOLO-Bari program
Approvals — FDA: no, EMA: no, PMDA: no
Description: APOLO-Bari program for one year in addition to treatment as usual
Study: 17190530
Drug: Eletriptan 20
Normalized name: eletriptan 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eletriptan 20 mg
Study: 16982287
Drug: Eletriptan 40
Normalized name: eletriptan 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eletriptan 40 mg
Study: 16982287
Drug: Eletriptan 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eletriptan 80 mg
Study: 12772414
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (traditional methods including hyperbaric oxygen, vasodilator, energy preparation such as ATP, CoA, and dexamethasone)
Study: 9135404
Drug: Inhaled 100%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled 100% oxygen
Study: 9135404
Drug: Inhaled air
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled air (control)
Study: 8201695
Drug: Postoperative cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative cisplatin chemotherapy (3 courses of 90 mg/m² given for 3 consecutive days at monthly intervals)
Study: 8201695
Drug: Postoperative cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative cisplatin chemotherapy
Study: 8201695
Drug: Postoperative cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative cisplatin chemotherapy and Observation
Study: 3284752
Drug: Mianserin (30-80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mianserin (30-80 mg daily)
Study: 3284752
Drug: Trazodone (150-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone (150-400 mg daily)
Study: 1297641
Drug: Controlled-release naproxen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release naproxen (750-mg tablet) after fasting
Study: 1297641
Drug: Controlled-release naproxen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release naproxen (750-mg tablet) after a standard meal
Study: 1297641
Drug: Controlled-release naproxen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release naproxen with food
Study: 1297641
Drug: Controlled-release naproxen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release naproxen fasting vs postprandial
Study: 26597952
Drug: Edaravone (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edaravone (30 mg twice per day for 14 days)
Study: 26597952
Drug: Control (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (100 ml saline twice per day for 14 days)
Study: 18836845
Drug: Serum procalcitonin
Normalized name: Procalcitonin
DrugBank: Procalcitonin (DB14812)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum procalcitonin (PCT) with a cut-off value of 0.85 ng/ml
Study: 17164307
Drug: Testosterone therapy
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone therapy (10 g testosterone gel daily for 24 weeks)
Study: 15976211
Drug: Preoperative field
Normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative field block plus rofecoxib, 50 mg preoperatively and for 5 days postoperatively (PLR)
Study: 11999936
Drug: Powered toothbrush
Normalized name: Pro Clean Spinbrush Powered Toothbrush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powered toothbrush fitted with a modified orthodontic brush head (Braun Oral-B Plaque Remover 3D)
Study: 10210035
Drug: Vigabatrin (VGB,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vigabatrin (VGB, 2‐4 g daily)
Study: 10210035
Drug: Sodium Valproate
Normalized name: sodium valproate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium Valproate (VPA, 1‐2 g daily)
Study: 7790126
Drug: Self-reported illicit
Normalized name: Illicium difengpi bark extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-reported illicit drug use
Study: 30765389
Drug: Pazopanib with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib with concomitant GAS therapy
Study: 30765389
Drug: Pazopanib without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib without concomitant GAS therapy
Study: 28604926
Drug: ADS-5102 (amantadine)
Normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ADS-5102 (amantadine) 274 mg administered orally at bedtime for up to 25 weeks
Study: 28833562
Drug: ADS-5102 (amantadine)
Normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ADS-5102 (amantadine) 274 mg
Study: 25353053
Drug: Tadalafil (TAD)
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tadalafil (TAD) 5mg coadministered with finasteride (FIN) 5mg once daily for 26 weeks
Study: 25353053
Drug: Placebo (PBO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PBO) coadministered with finasteride (FIN) 5mg once daily for 26 weeks
Study: 20593411
Drug: AMG 785
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 785 (0.1, 0.3, 1, 3, 5, or 10 mg/kg subcutaneously or 1 or 5 mg/kg intravenously)
Study: 17483532
Drug: Glatiramer acetate
Normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glatiramer acetate (GA) 20 mg subcutaneously daily
Study: 15470215
Drug: Lamivudine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine (100 mg per day)
Study: 9583069
Drug: Laparoscopic retroperitoneal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laparoscopic retroperitoneal uterine suspension (n = 32)
Study: 7637176
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg of droperidol added to buprenorphine
Study: 7637176
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg of droperidol added to buprenorphine
Study: 7637176
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of droperidol added to buprenorphine
Study: 2759074
Drug: Isotonic glucose-electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic glucose-electrolyte solution
Study: 17375008
Drug: 595 nm
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 595 nm pulse dye laser therapy (PDL) with settings: spot diameter 5 mm, pulse duration 0.45 ms, fluence 9 J/cm2, 5 passes at 1 Hz, with cryogen spray cooling.
Study: 17375008
Drug: 595 nm
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 595 nm pulse dye laser therapy (PDL)
Study: 7650078
Drug: iohexol 300
Normalized name: IOHEXOL 300MG/ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: iohexol 300 mgI/ml (100 ml, n = 17)
Study: 7650078
Drug: ioversol 320
Normalized name: IOVERSOL 320MG/ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: ioversol 320 mgI/ml (100 ml, n = 13)
Study: 7650078
Drug: iopromide 300
Normalized name: IOPROMIDE 300mgI/ml INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: iopromide 300 mgI/ml (75 ml, n = 12)
Study: 7650078
Drug: iopentol 300
Normalized name: iopentol 300 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: iopentol 300 mgI/ml (100 ml, n = 11)
Study: 342692
Drug: L-histidine 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-histidine 4.5 g daily for 30 weeks
Study: 31419622
Drug: Multi-component nurse-led
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-component nurse-led intervention including nurse-led care coordination, nurse-managed medication protocols and adherence support, home BP monitoring, and electronic health records support tools.
Study: 28095832
Drug: Motion-sensor biofeedback
Normalized name: GLUCOSE SENSOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motion-sensor biofeedback treatment in addition to guidelines-based care
Study: 26383176
Drug: Control therapy
Normalized name: Benzoyl Peroxide;Salicylic Acid;Vitamin E 8%; 2%; 5% Topical application Kit [INOVA 8/2 ACNE CONTROL THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control therapy 3 times a week for 4 weeks
Study: 23149074
Drug: Gazpacho consumption
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gazpacho consumption (250 g/week increase)
Study: 18470670
Drug: No additive
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additive treatment (Control)
Study: 10719612
Drug: 360 mg
Normalized name: aspirin 360 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 360 mg AS 195
Study: 10719612
Drug: 720 mg
Normalized name: pancreatin 720 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 720 mg AS 195
Study: 10719612
Drug: 360 mg
Normalized name: aspirin 360 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 360 mg AS 195 and 720 mg AS 195
Study: 3677541
Drug: Nicainoprol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicainoprol (100 mg intravenous infusion)
Study: 3677541
Drug: Nicainoprol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicainoprol (200 mg oral dose)
Study: 3677541
Drug: Nicainoprol (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicainoprol (both doses)
Study: 24903387
Drug: Renin-angiotensin inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renin-angiotensin inhibitors
Study: 3246461
Drug: L-tryptophan supplementation
Normalized name: L-TRYPTOPHAN
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-tryptophan supplementation
Study: 10319775
Drug: Low-dose sevoflurane
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose sevoflurane (end-tidal concentration, 0.25%)
Study: 6783419
Drug: Cholestyramine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholestyramine administration
Study: 7588486
Drug: Neomycin administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neomycin administration
Study: 2277372
Drug: 80‐mg terconazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80‐mg terconazole suppositories for 3 days
Study: 2277372
Drug: Miconazole nitrate
Normalized name: Miconazole Nitrate
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Miconazole nitrate suppositories for 7 days
Study: 2277372
Drug: Placebo suppositories
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo suppositories for 7 days
Study: 6985830
Drug: Weekly cyclophosphamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly cyclophosphamide, cytosine arabinoside, and methotrexate (CAM)
Study: 6985830
Drug: Twice daily
Normalized name: CAPSULE, TWICE DAILY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily cytosine arabinoside and thioguanine (AT)
Study: 6985830
Drug: Overall response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Overall response rate for both treatments
Study: 11758850
Drug: UFT 300
Normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT 300 mg/m2/day with oral Folinic acid 7.5 mg/dose for 21 days
Study: 9212017
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy followed by concurrent treatment (Arm 1): vinblastine (VB) 5 mg/M2 I.V. bolus weekly for weeks 1-5, cisplatin (DDP) 100 mg/M2 days 1 and 29, DDP 75 mg/M2 days 50, 71, and 92, with daily RT starting on day 50 (total dose 63 Gy in 34 fractions over 7 weeks).
Study: 9212017
Drug: Immediate concurrent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate concurrent chemotherapy/radiotherapy (Arm 2): RT started on day 1 (total dose 69.6 Gy in 58 fractions of 1.2 Gy bid, 5 days per week for 6 weeks), DDP 50 mg/M2 i.v. days 1 and 8, oral VP-16 50 mg b.i.d. during the first 10 days of RT, repeated beginning day 29.
Study: 2906171
Drug: Norfloxacin 400
Normalized name: norfloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin 400 mg twice daily for 3 days
Study: 29289726
Drug: Annual application
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual application of 30% SDF solution
Study: 29289726
Drug: Three applications
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three applications of 30% SDF at weekly intervals
Study: 29289726
Drug: Three applications
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three applications of 5% NaF varnish at weekly intervals
Study: 17196048
Drug: Topiramate (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiramate (25 to 400 mg/day over 8 weeks, continued for 4 additional weeks)
Study: 14751054
Drug: i.v. Anqi
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. Anqi and oral consecutive strategy
Study: 11202421
Drug: Papaverine 30
Normalized name: papaverine 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Papaverine 30 mg + phentolamine 1 mg (Control)
Study: 8992678
Drug: Lysine acetylsalicylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysine acetylsalicylate (900 mg) + Metoclopramide (10 mg)